A Phase 1 interventional study of Carbidopa and Levodopa Controlled-Release Tablets (25 mg/150 mg) and Carbidopa and Levodopa Controlled-Release Tablets (25 mg/150 mg) in Healhty, sponsored by Shanghai WD Pharmaceutical Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-23.
Sponsored by Shanghai WD Pharmaceutical Co., Ltd. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
WD-1603 contains two different drugs called levodopa and carbidopa in one tablet. The goal of this clinical trial is to see if taking the study drug WD-1603 at different time intervals affects how the drug acts in healthy volunteers. We also want to learn about the safety of WD-1603.
The main question we want to answer is:
This trial is a multiple-dose, open-label, sequential, three-period pharmacokinetic study comparing different dosing intervals of WD-1603 in healthy participants.
The purpose of the study is:
This Phase I clinical trial is planned to enroll 12 healthy participants, with an appropriate proportion of female participants (at least one quarter, i.e., 3 participants).
Pharmacokinetic parameters will be calculated using Phoenix WinNonlin (version 8.3 or higher), and other analyses will be performed using SAS software (version 9.4 or higher). Using PKS, an analysis of variance (ANOVA) is performed on the natural log-transformed Cmax, AUC0-τ, and ΔC0.5. The model includes dosing occasion as a fixed effect and participant as a random effect. The 90% confidence interval for the geometric mean ratio (second dose/first dose) of each parameter is calculated.
Shanghai WD Pharmaceutical Co., Ltd. is the lead sponsor of 3 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cohort 1: Participants will take one WD-1603 25 mg/150 mg tablet orally 5 minutes before each meal, twice daily with a 5-hour interval between doses, over a 1-day dosing period.
Drug: Carbidopa and Levodopa Controlled-Release Tablets (25 mg/150 mg)
Cohort 2: Participants will take one WD-1603 25 mg/150 mg tablet orally 5 minutes before each meal, twice daily with a 6-hour interval between doses, over a 1-day dosing period.
Drug: Carbidopa and Levodopa Controlled-Release Tablets (25 mg/150 mg)
Cohort 3: Participants will take one WD-1603 25 mg/150 mg tablet orally 5 minutes before each meal, twice daily with a 7-hour interval between doses, over a 1-day dosing period.
Drug: Carbidopa and Levodopa Controlled-Release Tablets (25 mg/150 mg)
Administered twice daily for one day with a 5-hour interval between doses.
Administered twice daily for one day with a 6-hour interval between doses.
Administered twice daily for one day with a 7-hour interval between doses.
Maximal Plasma Concentration (Cmax) of Carbidopa and Levodopa
Maximal plasma concentration (Cmax) of carbidopa and levodopa after two doses of WD-1603 administered orally before meals at different dosing intervals in healthy participants.
Time frame: 24 hours after the first dose.
Area under the Concentration versus Time Curve from 0 to Time t (AUC0-t) of Carbidopa and Levodopa
Area under the concentration versus time curve from 0 to time t (AUC0-t) of carbidopa and levodopa after two doses of WD-1603 administered orally before meals at different dosing intervals in healthy participants.
Time frame: 24 hours after the first dose.
Area under the Concentration versus Time Curve from 0 Extrapolated to Infinity (AUC0-∞) of Carbidopa and Levodopa
Area under the concentration versus time curve from 0 extrapolated to infinity (AUC0-∞) of carbidopa and levodopa after two doses of WD-1603 administered orally before meals at different dosing intervals in healthy participants.
Time frame: 24 hours after the first dose.
Time to Maximal Plasma Concentration (tmax) of Carbidopa and Levodopa
Time to maximal plasma concentration (tmax) of carbidopa and levodopa after two doses of WD-1603 administered orally before meals at different dosing intervals in healthy participants.
Time frame: 24 hours after the first dose.
Elimination Half-life (t1/2) of Carbidopa and Levodopa
Elimination half-life (t1/2) of carbidopa and levodopa after two doses of WD-1603 administered orally before meals at different dosing intervals in healthy participants.
Time frame: 24 hours after the first dose.
Terminal Elimination Rate Constant (λz) of Carbidopa and Levodopa
Terminal elimination rate constant (λz) of carbidopa and levodopa after two doses of WD-1603 administered orally before meals at different dosing intervals in healthy participants.
Time frame: 24 hours after the first dose.
Apparent Clearance (CL/F) of Carbidopa and Levodopa
Apparent clearance (CL/F) of carbidopa and levodopa after two doses of WD-1603 administered orally before meals at different dosing intervals in healthy participants.
Time frame: 24 hours after the first dose.
Apparent Volume of Distribution (Vd/F) of Carbidopa and Levodopa
Apparent volume of distribution (Vd/F) of carbidopa and levodopa after two doses of WD-1603 administered orally before meals at different dosing intervals in healthy participants.
Time frame: 24 hours after the first dose.
Cmax of Levodopa and Carbidopa for Each Dose
Cmax of carbidopa and levodopa for each dose after two doses of WD-1603 administered orally before meals at different dosing intervals in healthy participants.
Time frame: 24 hours after the first dose.
AUC0-τ of Levodopa and Carbidopa for Each Dose
AUC0-τ of carbidopa and levodopa for each dose after two doses of WD-1603 administered orally before meals at different dosing intervals in healthy participants, where τ is the dosing interval.
Time frame: 24 hours after the first dose.
Ratio of ΔC0.5 between the Two Doses
Ratio of ΔC0.5 of carbidopa and levodopa between the two doses after two doses of WD-1603 administered orally before meals at different dosing intervals in healthy participants, where the ΔC0.5 of the first dose is equal to the concetration at 0.5 hour C0.5; the ΔC0.5 of the second dose is the difference between the concontration at t+0.5 hours (Ct+0.5) and the concentration at t (Ct) (t is the dosing interval).
Time frame: 24 hours after the first dose.
Number and Percentage of Participants for Each Type of Adverse Events (AEs)
All AEs will be coded using MedDRA version 28.1 or higher to provide the System Organ Class (SOC) and Primary Term (PT) for each event. AEs will be summarized by treatment period, including the number and percentage of participants for each event category and for treatment-related adverse events. Additionally, summarize treatment-emergent adverse events (TEAEs) by treatment period for deaths, serious adverse events (SAEs), events leading to discontinuation of study medication, and events leading to early termination of the study.
Time frame: Throughout the study, about 21 days.
Number and Percentage of Participants with Abnormal Findings in Laboratory Tests, Physical Examinations, Vital Signs and 12-lead Electrocardiogram (12-lead ECG)
Summarize measurements recorded at each time point (screening, baseline, each visit, and study completion) along with changes from baseline at each visit and study completion. Use cross-tabulation to summarize baseline values for each indicator and the most clinically significant change determined post-treatment.
Time frame: Baseline, 1 week, 2 weeks and 3 weeks.
Plan to share: No
Ran from Mar 2026 to primary completion in Apr 2026, 1 month.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanghai WD Pharmaceutical Co., Ltd.